CL2014001730A1 - Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende. - Google Patents
Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende.Info
- Publication number
- CL2014001730A1 CL2014001730A1 CL2014001730A CL2014001730A CL2014001730A1 CL 2014001730 A1 CL2014001730 A1 CL 2014001730A1 CL 2014001730 A CL2014001730 A CL 2014001730A CL 2014001730 A CL2014001730 A CL 2014001730A CL 2014001730 A1 CL2014001730 A1 CL 2014001730A1
- Authority
- CL
- Chile
- Prior art keywords
- epirregulin
- antibody
- vector
- production
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011287654 | 2011-12-28 | ||
JP2012133394 | 2012-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2014001730A1 true CL2014001730A1 (es) | 2014-10-17 |
Family
ID=48697597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2014001730A CL2014001730A1 (es) | 2011-12-28 | 2014-06-26 | Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende. |
Country Status (23)
Country | Link |
---|---|
US (2) | US9556264B2 (es) |
EP (1) | EP2799543A4 (es) |
JP (2) | JP6010551B2 (es) |
KR (1) | KR20140107610A (es) |
CN (1) | CN104136610B (es) |
AU (1) | AU2012361510B9 (es) |
BR (1) | BR112014015581A2 (es) |
CA (1) | CA2862254A1 (es) |
CL (1) | CL2014001730A1 (es) |
CO (1) | CO7101193A2 (es) |
CR (1) | CR20140352A (es) |
HK (1) | HK1200187A1 (es) |
IL (1) | IL233368A0 (es) |
MX (1) | MX350044B (es) |
MY (1) | MY172428A (es) |
PE (1) | PE20141560A1 (es) |
PH (1) | PH12014501468A1 (es) |
RU (1) | RU2634383C2 (es) |
SG (2) | SG10201508095UA (es) |
TW (1) | TWI593705B (es) |
UA (1) | UA115046C2 (es) |
WO (1) | WO2013100120A1 (es) |
ZA (1) | ZA201405405B (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007312367B2 (en) | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
BR112013032630B1 (pt) | 2011-06-30 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídeo heterodimerizado compreendendo região fc de igg |
EP3603671A3 (en) | 2011-10-28 | 2020-07-29 | Chugai Seiyaku Kabushiki Kaisha | Cancer stem cell-specific molecule |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
DK2940135T5 (da) | 2012-12-27 | 2021-09-20 | Chugai Pharmaceutical Co Ltd | Heterodimeriseret polypeptid |
CN105517571A (zh) * | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
TWI787590B (zh) * | 2013-12-27 | 2022-12-21 | 日商中外製藥股份有限公司 | 等電點低之抗體的精製方法 |
BR112016025312A2 (pt) * | 2014-05-01 | 2017-10-17 | Genentech Inc | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem |
EP3185004A4 (en) * | 2014-08-20 | 2018-05-30 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring viscosity of protein solution |
JP2019202936A (ja) * | 2016-08-17 | 2019-11-28 | 中外製薬株式会社 | 抗Epiregulin抗体と抗EGFR抗体との併用医薬 |
US20190382484A1 (en) | 2017-02-24 | 2019-12-19 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method |
CA3063344A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Novel cd73 antibody, preparation and uses thereof |
GB201803892D0 (en) * | 2018-03-12 | 2018-04-25 | Ultrahuman Six Ltd | C-met binding agents |
WO2020045545A1 (ja) | 2018-08-29 | 2020-03-05 | 中外製薬株式会社 | 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法 |
JPWO2020153467A1 (ja) * | 2019-01-24 | 2021-12-02 | 中外製薬株式会社 | 新規がん抗原及びそれらの抗原に対する抗体 |
JP7232707B2 (ja) | 2019-05-21 | 2023-03-03 | トーソー株式会社 | ブラケット構造 |
CN112574308A (zh) | 2019-09-30 | 2021-03-30 | 和铂医药(苏州)有限公司 | 靶向bcma的抗体、双特异性抗体及其用途 |
CN113150155B (zh) * | 2021-04-22 | 2022-04-08 | 安徽瀚海博兴生物技术有限公司 | 一种抗pd-l1人源化单克隆抗体及其应用 |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5190858A (en) | 1989-02-01 | 1993-03-02 | Oncogene Science, Inc. | Monoclonal antibodies directed to epitopes of human transforming growth factor--α and uses thereof |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
ES2246502T3 (es) | 1990-08-29 | 2006-02-16 | Genpharm International, Inc. | Animales no humanos transgenicos capaces de producir anticuerpos heterologos. |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
DK0605522T3 (da) | 1991-09-23 | 2000-01-17 | Medical Res Council | Fremgangsmåde til fremstilling af humaniserede antistoffer |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
DK1024191T3 (da) | 1991-12-02 | 2008-12-08 | Medical Res Council | Fremstilling af autoantistoffer fremvist på fag-overflader ud fra antistofsegmentbiblioteker |
CA2131151A1 (en) | 1992-03-24 | 1994-09-30 | Kevin S. Johnson | Methods for producing members of specific binding pairs |
ATE381614T1 (de) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5783417A (en) | 1993-06-04 | 1998-07-21 | Taisho Pharmaceutical Co., Ltd. | Human-derived tumor cell growth inhibitors |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
CA2177367A1 (en) | 1993-12-03 | 1995-06-08 | Andrew David Griffiths | Recombinant binding proteins and peptides |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
ES2304786T3 (es) | 1995-04-27 | 2008-10-16 | Amgen Fremont Inc. | Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados. |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
US6172213B1 (en) | 1997-07-02 | 2001-01-09 | Genentech, Inc. | Anti-IgE antibodies and method of improving polypeptides |
SK14812000A3 (sk) | 1998-04-03 | 2001-08-06 | Chugai Seiyaku Kabushiki Kaisha | Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
EP1189641B1 (en) | 1999-06-25 | 2009-07-29 | Genentech, Inc. | HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
CA2424602C (en) | 2000-10-06 | 2012-09-18 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-producing cell |
CU22979A1 (es) | 2000-12-08 | 2004-09-09 | Centro Inmunologia Molecular | Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
WO2003057881A1 (fr) | 2001-12-28 | 2003-07-17 | Chugai Seiyaku Kabushiki Kaisha | Procede de stabilisation d'une proteine |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP1514928B1 (en) | 2002-06-05 | 2013-07-31 | Chugai Seiyaku Kabushiki Kaisha | Method for producing antibodies using baculoviruses |
PT1517921E (pt) | 2002-06-28 | 2006-09-29 | Domantis Ltd | Ligandos duplamente especificos com semi-vida no soro aumentada |
BRPI0314814C1 (pt) | 2002-09-27 | 2021-07-27 | Xencor Inc | anticorpo compreendendo uma variante de fc |
ES2574993T3 (es) | 2003-01-22 | 2016-06-23 | Roche Glycart Ag | Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora |
RU2312109C2 (ru) * | 2003-03-14 | 2007-12-10 | Тайсо Фармасьютикал Ко., Лтд. | Моноклональное антитело и продуцирующая его гибридома |
US7195764B2 (en) | 2003-04-14 | 2007-03-27 | Arius Research Inc. | Cancerous disease modifying antibodies |
DK1704166T3 (en) | 2004-01-07 | 2015-06-01 | Novartis Vaccines & Diagnostic | M-CSF-SPECIFIC MONOCLONAL ANTIBODY AND APPLICATIONS THEREOF |
SV2006001990A (es) | 2004-01-09 | 2006-01-30 | Pfizer | Anticuerpos contra madcam |
DE602005015542D1 (de) | 2004-01-12 | 2009-09-03 | Applied Molecular Evolution | Varianten der fc-region |
WO2005076979A2 (en) | 2004-02-06 | 2005-08-25 | Wyeth | Diagnosis and therapeutics for cancer |
EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
US20090061485A1 (en) | 2004-12-22 | 2009-03-05 | Chugai Seiyaku Kabushiki Kaisha | Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited |
CN101365712A (zh) | 2005-01-11 | 2009-02-11 | 莫勒丘尔洛吉克斯有限公司 | Pan-HER拮抗剂及其使用方法 |
EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
CA2606102C (en) | 2005-04-26 | 2014-09-30 | Medimmune, Inc. | Modulation of antibody effector function by hinge domain engineering |
WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
EP1931709B1 (en) | 2005-10-03 | 2016-12-07 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
KR20090057936A (ko) | 2006-02-08 | 2009-06-08 | 타게티드 몰레큘라 다이아그노스틱스, 엘엘씨 | 2가 erbb 리간드 결합 분자 및 그의 제조 방법 및 사용방법 |
DK3056568T3 (da) | 2006-03-31 | 2021-11-01 | Chugai Pharmaceutical Co Ltd | Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik |
AU2007312367B2 (en) * | 2006-10-12 | 2012-09-06 | Chugai Seiyaku Kabushiki Kaisha | Diagnosis and treatment of cancer using anti-EREG antibody |
CN103408661B (zh) | 2007-01-05 | 2016-04-06 | 苏黎世大学 | 提供疾患特异性结合分子和靶的方法 |
WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
JP2009078946A (ja) | 2007-09-26 | 2009-04-16 | Fujifilm Corp | コア−シェル型金属酸化物粒子及びその製造方法 |
CL2008002886A1 (es) | 2007-09-26 | 2009-12-04 | Chugai Pharmaceutical Co Ltd | Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende. |
AU2008305851B2 (en) | 2007-09-28 | 2014-12-18 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican-3 antibody having improved kinetics in plasma |
EP2436397B1 (en) | 2009-05-29 | 2017-05-10 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition containing antagonist of egf family ligand as component |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
CN103328626B (zh) | 2010-10-06 | 2017-02-08 | 中外制药株式会社 | 癌干细胞群及其制备方法 |
BR112013032630B1 (pt) * | 2011-06-30 | 2022-06-14 | Chugai Seiyaku Kabushiki Kaisha | Polipeptídeo heterodimerizado compreendendo região fc de igg |
TWI593705B (zh) | 2011-12-28 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient |
CN105517571A (zh) | 2013-06-24 | 2016-04-20 | 中外制药株式会社 | 含有人源化抗上皮调节蛋白抗体作为有效成分的腺癌以外的非小细胞肺癌的治疗药 |
-
2012
- 2012-12-26 TW TW101150028A patent/TWI593705B/zh not_active IP Right Cessation
- 2012-12-28 MY MYPI2014701733A patent/MY172428A/en unknown
- 2012-12-28 EP EP12863154.6A patent/EP2799543A4/en not_active Withdrawn
- 2012-12-28 SG SG10201508095UA patent/SG10201508095UA/en unknown
- 2012-12-28 SG SG11201403565XA patent/SG11201403565XA/en unknown
- 2012-12-28 PE PE2014001036A patent/PE20141560A1/es not_active Application Discontinuation
- 2012-12-28 WO PCT/JP2012/084042 patent/WO2013100120A1/ja active Application Filing
- 2012-12-28 US US14/369,539 patent/US9556264B2/en not_active Expired - Fee Related
- 2012-12-28 CN CN201280070788.2A patent/CN104136610B/zh not_active Expired - Fee Related
- 2012-12-28 BR BR112014015581-0A patent/BR112014015581A2/pt not_active IP Right Cessation
- 2012-12-28 MX MX2014008009A patent/MX350044B/es active IP Right Grant
- 2012-12-28 JP JP2013551852A patent/JP6010551B2/ja not_active Expired - Fee Related
- 2012-12-28 RU RU2014130766A patent/RU2634383C2/ru not_active IP Right Cessation
- 2012-12-28 KR KR20147020786A patent/KR20140107610A/ko not_active Application Discontinuation
- 2012-12-28 CA CA2862254A patent/CA2862254A1/en not_active Abandoned
- 2012-12-28 UA UAA201408353A patent/UA115046C2/uk unknown
- 2012-12-28 AU AU2012361510A patent/AU2012361510B9/en not_active Ceased
-
2014
- 2014-06-25 PH PH12014501468A patent/PH12014501468A1/en unknown
- 2014-06-25 IL IL233368A patent/IL233368A0/en unknown
- 2014-06-26 CL CL2014001730A patent/CL2014001730A1/es unknown
- 2014-07-22 ZA ZA2014/05405A patent/ZA201405405B/en unknown
- 2014-07-22 CR CR20140352A patent/CR20140352A/es unknown
- 2014-07-24 CO CO14161083A patent/CO7101193A2/es unknown
-
2015
- 2015-01-16 HK HK15100507.9A patent/HK1200187A1/xx not_active IP Right Cessation
-
2016
- 2016-09-15 US US15/266,829 patent/US20170129950A1/en not_active Abandoned
- 2016-09-16 JP JP2016181435A patent/JP6329601B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2014001730A1 (es) | Anticuerpo anti-epirregulina humanizado; vector; celula huesped; metodo de produccion; composicion farmaceutica que lo comprende; y agente terapeutico contra el cancer que lo comprende. | |
CL2014001345A1 (es) | Metodos de tratamiento usando un anticuerpo contra interferon gamma; usos composicion farmaceutica que contiene un anticuerpo contra interferon gamma. | |
HK1220980A1 (zh) | 用於治療龐貝氏症的方法和組合物 | |
WO2013114367A8 (en) | C10rf32 antibodies, and uses thereof for treatment of cancer | |
CL2014002549A1 (es) | Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados. | |
IL239735B (en) | A pharmaceutical preparation for the treatment of diseases related to toxic aldehyde | |
BR112014009634A2 (pt) | preparação e agente terapêutico | |
BR112014015003A2 (pt) | composição farmacêutica, método para tratar um cancer e método para reduzir o tamanho de uma massa tumoral | |
AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
UA115034C2 (uk) | Імунокон'югат для застосування в лікуванні раку або запального порушення | |
BR112015007120A2 (pt) | anticorpo biespecífico, composição farmacêutica, uso, célula hospedeira e método de produção de um anticorpo | |
BR112013030472A2 (pt) | formulação farmacêutica, artigo de fabricação e método | |
EP3010486A4 (en) | Chemical structures for localized delivery of therapeutic agents | |
CL2012000524A1 (es) | Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo. | |
EP3057594A4 (en) | Method of treating cancer | |
EP2700652A4 (en) | DIAGNOSIS AND TREATMENT OF CANCER BY ANTI-ITM2A ANTIBODIES | |
BR112014012498A2 (pt) | anticorpo anti-cd20 e método para o tratamento do câncer | |
HK1201855A1 (en) | Antibodies and methods of treating cancer | |
EP2996721A4 (en) | Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer | |
EP3006465A4 (en) | Anti-vegf antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same | |
EP3020828A4 (en) | Method of predicting response of cancer to treatment | |
EP3004396A4 (en) | Methods and compositions for the treatment of cancer | |
EP3074040A4 (en) | Method of treating cancer | |
ITTO20120461A1 (it) | Agente per il controllo di ectoparassiti di animali. | |
EP3015864A4 (en) | Biomarkers for the diagnosis and the response to treatment of pancreatic cancer |